INSL5 and diabetes mellitus: However, to date, no RXFP4-specific antagonist (peptide or small molecule) has been reported in the literature and such a compound would be enormously valuable to understand the physiology of INSL5 and validate RXFP4 as potential therapeutic target for the treatment of human conditions such as obesity and diabetes.